MPN Hub expands content to enhance global knowledge of myeloproliferative neoplasms throughout Q3 of 2021

Press Release: Available for Immediate Release

The MPN Hub, run by Scientific Education Support (SES) in partnership with the European LeukemiaNet (ELN), is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education in myeloproliferative neoplasms (MPN). The MPN Hub aims to enhance knowledge of MPN through the dissemination of advances related to their classification, diagnosis, treatment, and management via multiple channels. Throughout Q3 of 2021, the MPN Hub has continued to promote significant developments in the research and treatment of myeloproliferative neoplasms.

Speaking about the hub’s activity, Mia Hill, IME Director at Scientific Education Support, said:

“During the last quarter, the MPN Hub expanded coverage of new unmet needs, with content on special populations in MPN and rare MPN subtypes, such as systemic mastocytosis. We also virtually attended two key congresses—the Texas MPN Workshop Second Annual Meeting, held on August 19–20, and the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, held on September 8–11—where we provided extensive live Twitter coverage, expert interviews across key clinical topics relating to MPN, and provided written summary articles on key talks. Our congress coverage generated over 35,000 impressions and over 500 direct website users, highlighting the relevance and impact of our coverage.”

The MPN Hub would like to thank its supporters—Bristol Myers Squibb, CTI BioPharma, Novartis, Kartos Therapeutics, AOP Orphan, Constellation Pharmaceuticals, Geron, and Sierra Oncology—without whom the platform would not be possible. During the last quarter, we also welcomed AbbVie as a Silver supporter and would like to extend a special thanks for their support going forward.

For more information on the MPN Hub, please visit mpn-hub.com.

For media enquiries or to explore opportunities for collaboration, please contact or neoplasms (MPNs) are a group of rare blood cancers where the body produces too many red blood cells, white blood cells, or platelets. The three main types include myelofibrosis, polycythemia vera, and essential thrombocythemia.

The MPN Hub, founded in partnership with the European LeukemiaNet (ELN) and run by Scientific Education Support (SES), is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MPN. Our aim is to enhance knowledge of MPN through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

The MPN Hub enables time-stretched HCPs to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, the MPN Hub supports HCPs worldwide.

The MPN Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

Funding for our hubs is made possible through financial support from the pharmaceutical industry. ​All content is developed by SES in collaboration with an expert steering committee. ​All content is independent, and the educational supporters are allowed no influence on the content.​

If you are interested in becoming an MPN supporter, please contact is a medical education company providing projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through the Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hematological-oncology, including the ALL Hub, AML Hub, GvHD Hub, Lymphoma Hub, MDS Hub, and Multiple Myeloma Hub.

The European LeukemiaNet cooperates with 220 participating centers in 44 countries, with more than 1,000 researchers and clinicians. The objective is to integrate about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry, and small and SMEs across Europe to form a network promoting cooperative research for curing leukemia.